Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Radiat Res ; 160(2): 152-8, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12859225

ABSTRACT

In the present study, we investigated the induction of genotoxic effects in human peripheral blood lymphocytes after exposure to electromagnetic fields used in mobile communication systems (frequency 900 MHz). For this purpose, the incidence of micronuclei was evaluated by applying the cytokinesis-block micronucleus assay. Cytotoxicity was also investigated using the cytokinesis-block proliferation index. The experiments were performed on peripheral blood from 20 healthy donors, and several conditions were tested by varying the duration of exposure, the specific absorption rate (SAR), and the signal [continuous-wave (CW) or GSM (Global System of Mobile Communication) modulated signal]. The following exposures were carried out: (1) CW intermittent exposure (SAR = 1.6 W/kg) for 6 min followed by a 3-h pause (14 on/off cycles); (2) GSM signal, intermittent exposure as described in (1); (3) GSM signal, intermittent exposure as described in (1) 24 h before stimulation with phytohemagglutinin (8 on/off cycles); (4) GSM signal, intermittent exposure (SAR = 0.2 W/kg) 1 h per day for 3 days. The SARs were estimated numerically. No statistically significant differences were detected in any case in terms of either micronucleus frequency or cell cycle kinetics.


Subject(s)
Lymphocytes/pathology , Lymphocytes/radiation effects , Radio Waves , Adult , Age Factors , Aged , Cell Cycle/radiation effects , Cell Division/drug effects , Cell Division/radiation effects , Cell Phone , Cells, Cultured , Cytochalasin B , Dose-Response Relationship, Radiation , Female , Humans , Lymphocytes/drug effects , Male , Micronuclei, Chromosome-Defective/radiation effects , Micronuclei, Chromosome-Defective/ultrastructure , Micronucleus Tests/methods , Middle Aged , Mutagenicity Tests/methods , Radiation Dosage
2.
Minerva Stomatol ; 40(3): 125-7, 1991 Mar.
Article in Italian | MEDLINE | ID: mdl-1870548

ABSTRACT

A case of mandibular osteomyelitis in a child affected by osteopetrosis is presented. Systemic antibiotic therapy was ineffective and surgery was required to obtain a partial control of infection.


Subject(s)
Mandibular Diseases/diagnosis , Osteomyelitis/diagnosis , Osteopetrosis/diagnosis , Anti-Bacterial Agents/therapeutic use , Child, Preschool , Chin , Combined Modality Therapy , Humans , Male , Mandibular Diseases/surgery , Osteomyelitis/surgery , Osteopetrosis/surgery , Postoperative Care
3.
Lancet ; 336(8714): 533-4, 1990 Sep 01.
Article in English | MEDLINE | ID: mdl-1975040

ABSTRACT

An evaluation was made of the possible relation between renal thromboxane (Tx)A2 synthesis (measured as urinary excretion of TxB2) and the loss of glomerular permeability to proteins, in 5 children with seven episodes of minimal change nephrotic syndrome. Urinary TxB2 excretion was significantly higher in children with minimal change nephrotic syndrome than in 14 healthy controls, and reached its maximum at the time of peak proteinuria. During remission of nephrotic syndrome urinary excretion of TxB2 was still significantly higher than in healthy controls. A significant positive correlation between urinary excretion of TxB2 and proteinuria was observed in 3 patients. The results suggest that renal TxA2 could be regarded as one of the possible mediators of the altered glomerular permeability to proteins in minimal change nephrotic syndrome.


Subject(s)
Kidney/metabolism , Nephrosis, Lipoid/metabolism , Thromboxane A2/biosynthesis , Child , Female , Humans , Male , Nephrosis, Lipoid/urine , Proteinuria , Thromboxane B2/urine
4.
Headache ; 30(5): 264-8, 1990 Apr.
Article in English | MEDLINE | ID: mdl-2191938

ABSTRACT

An 8-month, double-blind, placebo-controlled crossover trial was carried out on the use of nimodipine in migraine prophylaxis in 37 patients aged 7 to 18 years old. After a 4-week medication-free run-in period, 19 subjects (Group 1) received a placebo while 18 (Group 2) received nimodipine (10-20 mg t.i.d., according to body weight), for 12 weeks. After a 4-week wash-out period, the groups switched therapy for a further 12 weeks. 30 patients completed the trial and the number of dropouts was comparable in the 2 groups. The only side-effect during nimodipine treatment was mild abdominal discomfort (3 cases). The treatments were evaluated on the basis of frequency and duration of attacks. There was a significant reduction in both parameters during the first period of treatment. During the second period of treatment, nimodipine proved to have a significantly greater effect than the placebo with regard to frequency, whereas the response was similar with the placebo as regards duration of attacks. The latter parameter shows a significant decrease during the treatment periods, regardless of type of therapy.


Subject(s)
Migraine Disorders/drug therapy , Nimodipine/therapeutic use , Adolescent , Child , Clinical Trials as Topic , Female , Humans , Male , Migraine Disorders/physiopathology , Placebos , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...